ReviewJournal of metabolic and bariatric surgery2022
Prevention of Gallstones After Bariatric Surgery using Ursodeoxycholic Acid: A Narrative Review of Literatures.
Review in Journal of metabolic and bariatric surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- The Relationship Between Bariatric Surgery and Gallbladder Cancer (GBC): A Systematic Review and Meta-analysis.Obesity surgery · 2026Pooled it
- Comparative Risk of Gallstone Formation After Sleeve Gastrectomy and Roux-En-Y Gastric Bypass: A Systematic Review and Meta-Analysis.Obesity surgery · 2025Pooled it
- Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations.Journal of obesity & metabolic syndrome · 2026Review
- Biliopancreatic limb obstruction secondary to 9 cm gallstone nearly two decades following open Roux-en-Y gastric bypass and cholecystectomy: a rare and challenging case.Journal of surgical case reports · 2025Article
- Pregnancy After Bariatric Surgery: Hepatobiliary Implications, Maternal Outcomes, and Clinical Considerations.Cureus · 2025Review
- Synergistic Integration of Multimodal Metabolic and Bariatric Interventions Transforming Transplant Care.Journal of clinical medicine · 2025Review
- Association between hereditary spherocytosis and gallstone disease: Pathophysiology, diagnosis, and management.World journal of gastrointestinal surgery · 2025Review
- Incidence of Gallstones in Patients with Obesity After Bariatric Surgery in Northern Saudi Arabia: A Cross-Sectional Study.Clinics and practice · 2025Article
- Complications of Metabolic and Bariatric Surgery for the Gastroenterologist: A Comprehensive Review.Gastroenterology & hepatology · 2025Article
- Adverse events of ursodeoxycholic acid: a real-world pharmacovigilance study using FAERS (2004-2023).Frontiers in medicine · 2025Article
- Biliary complications associated with weight loss, cholelithiasis and choledocholithiasis.World journal of gastrointestinal pharmacology and therapeutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity by itself is a factor in the development of gallstone disease, and periods of weight loss after bariatric surgery further increase the risk of gallstone formation. In patients with obesity, hypersecretion of cholesterol may increase the risk of gallstone formation, which is approximately five-fold higher than that in the general population. The incidence of gallstone formation after bariatric surgery is 10-38% and often associated with a proportional increase in the risk of developing biliary complications. Routine postoperative administration of ursodeoxycholic acid (UDCA) is recommended to prevent gallstone formation. Several randomized trials have indicated that UDCA can effectively prevent gallstones and reduce the risk of cholecystectomy after bariatric procedures. The effective daily dose of UDCA in each study ranged from 500 to 1,200 mg, and it may be considered at least during the period of rapid weight loss (first 3-6 months postoperatively) to decrease the incidence of symptomatic gallstones.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.